Member Info for krull

$4 million

Haleon would of done there due diligence before handing over $4 upfront payment for the right to market eroxon in the US, there's a lot of advertising spend as well.

Good post PetitStVincent,

My understanding is, Futura manufacture the product using 3rd parties, then sell this to the distributors/marketers. With Haleon looking to launch from H2 2024, It would be reasonable to assume, Haleon would need a lot of stock in place ready for distribution!

Looks like some wise old owl's here, are selling some UJO and following David Bramhill (reading between the lines tip) to buy Beacon.

After meeting with their management, I wonder if David bought Beacon for his personal account as well.

Nudge Nudge, Wink Wink.

Https://www.voxmarkets.co.uk/articles/destiny-pharma-sharpens-focus-on-lead-asset-partnerships--8a3181b/

It's a lucky thing the market thinks ahead, so should see the share price move ahead before then, the early bird catches the worm so to speak.

I do agree though, was poor PR

Martinelwick, this my take on you question, It's traders selling on the news, (a common thing) they set the ball running and some investors get spooked and follow.

It's perceived, once the news event is done, there will be no news for a while, which equals share price drifting lower.

However, I believe there will be lots of news flow here, plenty of new territories/country's to announce product approvals, more distribution agreements with upfront payments and millstone objective payments. Also, maybe some surprise positive news on new eroxon application's and formula's, and new product advancement. And of course, a big phama offering to buy us out for 2 billion, LOL.

Nothing unexpected in the RNS.

It's just traders selling on the news, the presentation will give some insight into deals in the making, might have them scrambling back on board.

On 20 September 2023, the Company will host a briefing for analysts at 8.30am BST, followed by a presentation to all existing and potential shareholders at 11.00am BST held via the Investor Meet Company platform. Further details for the analyst briefing will be shared by invitation in due course.

Damn it nofear52, you've put this song in my head now LOL.

https://www.youtube.com/watch?v=vjD3EVC1-zU&pp=ygUXdGhlIG9ubHkgd2F5IGlzIHVwIHlheno%3D

Thanks Jet, I'm looking forward to plenty of upcoming news flow events before Aprils update, like upfront payments by new partner agreements, new country launches. Maybe even millstone payments met.

Alamo55, I'm happy to listen to genuine information, positive or negative, however I don't accept British Bulls opinion as credence, what ever stance they take.

What is this mumbo jumbo: The outline again looks like a pregnant woman, as with the Bullish Harami Pattern. However, now the baby is a Doji. Basically, the pattern is characterized by a black body followed by a Doji that is completely inside the range of the prior black body.

Iv'e got no interest in what British Bulls are saying/predicting.

I for one would be grateful if you didn't post their opinion.

Maybe eroxon could help Viagra work better

Reviews are addressed/explained in this video

Fireside Chat with James Barder, CEO of Futura Medical July 2023

https://futuramedical.com/investor-centre/videos-and-webcasts/videos/

Unless I'm not hearing/understanding this right, in this fireside chat around 07.10 in, to quote what the CEO is saying: We are getting complaints in about one in ten thousand packs sold!!!

Unfortunately it seems to be only available via the website.

listening to this interview for the first time, I found it interesting, it address some of the negative feedback from buyers of eroxon.

https://futuramedical.com/investor-centre/videos-and-webcasts/videos/

Interesting, however, I don't think we will be getting a retrace just before these upcoming events:

On 20 September 2023, the Company will host a briefing for analysts at 8.30am BST, followed by a presentation to all existing and potential shareholders at 11.00am BST held via the Investor Meet Company platform. Further details for the analyst briefing will be shared by invitation in due course.

Brighton, United Kingdom - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and treat life threatening infections, will announce its interim results for the period ended 30 June 2023 on Wednesday 20 September 2023.

Thank you Laguito, you made me think again, the mystery is solved, they spoke about it in this presentation, not the other one.

https://futuramedical.com/investor-centre/videos-and-webcasts/webcasts/

Yes quite right The.Italian, I listened to the presentation again, seems my memory was a bit blurred, what they actually talked about, was doing a deal with another company developing a femail sexual health product and dismissing it, there was nothing about developing in house. So I have no idea where Laguito got his information from! I must admit though, It looked genuine to me by the way it was written, also because it would seem quite logical for med3000 to arouse a femail C spot, in the same way as it would the male gland, after thinking more about it, the amount needed to be applied would be much less, so IMO sales for a dedicated femail product would be small, and most likely not worth putting through trials! However, if it does help a women have more fun, then it would surly help boost sales of Eroxon. Maybe someone reading the BB could do some home research and report back, LOL.